Biohaven is a modern pharmaceutical company that is dedicated to transforming the lives of people with unmet medical needs. They are committed to discovering and developing innovative therapies for neurological and neuropsychiatric diseases, including rare disorders. By challenging the status quo, Biohaven aims to provide life-changing treatments for individuals suffering from debilitating conditions.

Leveraging their proprietary platforms, they are at the forefront of advancing paradigm-shifting treatment options. With a strong focus on neurological conditions like obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA), and spinal muscular atrophy (SMA), Biohaven's multiple clinical trials are currently underway. Guided by science, they continuously evolve their approach to drug discovery and development, leveraging collaborations with esteemed institutions and licensing intellectual property.

With proven drug development capabilities and a culture of innovation, Biohaven is at the forefront of digital transformation in the pharmaceutical industry. They are on a mission to deliver breakthrough science, launch successful treatments, and build global partnerships